Maynard Um
-
-
-
-
-
-
-
Merus petosemtamab data selected for plenary session at cancer conference
-
-
-
-
-
-
-
Genmab A/S (GMAB) PT Raised to $34 at Leerink Partners
-
-
-
-
-
-
-
Barclays Starts Merus N.V. (MRUS) at Overweight
-
-
-
-
-
-
-
'Merus N.V. (MRUS) Changing the Game in HNSCC'; PT Raised to $110 at BMO Capital
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Merus N.V. (MRUS)
-
-
-
-
-
-
-
Merus N.V. (MRUS) PT Raised to $97 at Citi
-
-
-
-
-
-
-
Goldman Sachs Starts Merus N.V. (MRUS) at Buy
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

